USA – Takeda has formed a new partnership with Code Biotherapeutics to gain opt-in rights for four rare disease candidates in a deal worth up to US$2 billion. These treatments…
Read MoreCode Bio and Takeda collaborate to develop gene therapies for rare diseases
